Underscores IMDELLTRA as a Recognized Standard of Care Treatment for Patients With Extensive Stage Small Cell Lung Cancer That Has Progressed Accessibility StatementSkip Navigation Global Confirmatory Phase 3 DeLLphi-304 Trial Showed IMDELLTRA Reduced Risk of Death by 40% Compared to Chemotherapy THOUSAND OAKS, Calif., Nov. 19, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced today that the U.S. Food and Drug Administration (FDA) has granted full approval to IMDELLTRA (tarlatamab-dlle) for the treatment ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

分组1 - Pulmonx Corporation reported a quarterly loss of $0.34 per share, which was better than the Zacks Consensus Estimate of a loss of $0.40, representing an earnings surprise of +15.00% [1] - The company achieved revenues of $21.5 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 4.10% and showing an increase from $20.39 million year-over-year [2] - Over the last four quarters, Pulmonx has consistently surpassed consensus EPS and revenue estimates [2] 分组2 - The stock has underperformed significantly, losing about 69.2% since the beginning of the year, while the S&P 500 has gained 16.4% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.38 on revenues of $23.83 million, and for the current fiscal year, it is -$1.51 on revenues of $90.89 million [7] - The Medical Info Systems industry, to which Pulmonx belongs, is currently ranked in the top 20% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Pulmonx (NasdaqGS:LUNG) Q3 2025 Earnings Call November 12, 2025 04:30 PM ET Speaker3Hello, and thank you for standing by. Welcome to Pulmonx Q3 2025 earnings conference call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press st ...

Revenue and Financial Performance - Revenue for the three months ended September 30, 2025, was $21.5 million, a 5.4% increase from $20.4 million for the same period in 2024, with a gross margin of 74.7%[117] - For the nine months ended September 30, 2025, revenue was $67.9 million, up 13.2% from $60.0 million in the same period in 2024, with a gross margin of 73.0%[117] - Revenue increased by $1.1 million, or 5.5%, to $21.5 million for the three months ended September 30, 2025, compared to $20.4 million for the same period in 2024[145] - For the nine months ended September 30, 2025, revenue increased by $7.9 million, or 13.1%, to $67.9 million compared to $60.0 million in the same period in 2024[153] - Revenue from sales outside of the United States represented 36.8% of total revenue for the nine months ended September 30, 2025, compared to 32.4% for the same period in 2024[188] Net Loss and Financial Position - The company reported a net loss of $14.0 million for Q3 2025, compared to a net loss of $14.1 million in Q3 2024, and a net loss of $43.6 million for the nine months ended September 30, 2025, compared to $43.2 million for the same period in 2024[117] - As of September 30, 2025, the company had an accumulated deficit of $511.1 million and cash and cash equivalents of $76.5 million[117] - As of September 30, 2025, the company had cash and cash equivalents of $76.5 million, expected to fund operating expenses for at least 12 months[178] - Net cash used in operating activities was $25.3 million for the nine months ended September 30, 2025, primarily due to a net loss of $43.6 million[171] - The company expects to continue incurring net losses for the next several years and will require substantial additional funding[118] Expenses and Cost Management - Research and development expenses rose by $1.1 million, or 29.4%, to $4.8 million for the three months ended September 30, 2025, primarily due to increased clinical trial costs[148] - Selling, general and administrative expenses increased by $0.2 million, or 0.7%, to $25.6 million for the three months ended September 30, 2025, driven by higher advertising and marketing expenses[149] - Research and development expenses for the nine months ended September 30, 2025, increased by $1.3 million, or 9.9%, to $14.9 million, largely due to clinical trial costs[155] - Interest expense decreased by $0.3 million to $2.4 million for the nine months ended September 30, 2025, due to lower interest rates[157] - Interest expense on the CIBC Loan was $0.8 million for the three months ended September 30, 2025[168] Market and Operational Strategy - Approximately 93% of revenue for the nine months ended September 30, 2025, was generated in markets where the company sells directly[113] - The company is focused on expanding its commercial operations in the U.S. and internationally, with significant investments in sales and marketing[118] - The company has a dedicated patient reimbursement support team to assist in securing prior authorization approvals for treatments[125] - The company may undertake additional expenses to expand its commercial organization and enhance research and development efforts[177] Research and Development - The company is investing in research and development to enhance existing products and develop next-generation technologies, including the AeriSeal System, which is in a pivotal trial[129] Currency and Inflation Impact - A 10% change in foreign currency exchange rates would have impacted revenues by approximately $2.5 million and operating expenses by $1.6 million for the nine months ended September 30, 2025, resulting in a net impact of $0.9 million on net loss[188] - High inflation rates have led to increased costs in transportation, wages, and other operational expenses[189] - Inflation may affect the company's cost of labor, commercial support, manufacturing, and clinical trial expenditures[189] - The company does not believe inflation has materially impacted its financial position or results of operations to date[189] - If costs become subject to significant inflationary pressures, the company may struggle to offset these with increased revenues[189] - The inability to offset higher costs with increased revenues could harm the company's business and financial condition[189]

REDWOOD CITY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter of 2025 ended September 30, 2025. Recent Highlights Achieved worldwide revenue of $21.5 million in the third quarter of 2025, a 5% increase over the same period last year and an increase of 4% on a constant currency basisDelivered $7.5 million in international revenue ...

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgency to invest in AI technologies now [1][13] - The energy demands of AI technologies are highlighted as a critical concern, with data centers consuming as much energy as small cities, leading to potential crises in power supply [2][3] Investment Opportunity - A specific company is positioned as a key player in the AI energy sector, owning critical energy infrastructure assets that will benefit from the increasing energy demands of AI [3][7] - This company is not a chipmaker or cloud platform but is essential for supplying the energy needed for AI advancements [3][6] Market Position - The company is described as a "toll booth" operator in the AI energy boom, profiting from the surge in energy demand driven by AI technologies [4][5] - It is involved in U.S. LNG exportation, which is expected to grow under the current administration's energy policies [7] Financial Health - The company is noted for being debt-free and having a significant cash reserve, equating to nearly one-third of its market capitalization, which positions it favorably compared to other energy firms burdened with debt [8][10] - The stock is trading at less than 7 times earnings, indicating it is undervalued relative to its potential [10][12] Strategic Advantages - The company has a unique footprint in nuclear energy, which is seen as a future source of clean and reliable power [14] - It is capable of executing large-scale engineering, procurement, and construction projects across various energy sectors, enhancing its competitive edge [7][8] Market Trends - The article discusses the broader trends of AI infrastructure supercycles, onshoring driven by tariffs, and the surge in U.S. LNG exports as significant factors influencing the market [14] - The influx of talent into the AI sector is expected to drive continuous innovation and advancements, making investments in AI increasingly attractive [12]

Group 1: Penny Stocks Overview - Five penny stocks to watch include Beyond Meat, Strive, VSee Health, Pulmonx, and Datavault AI, identified by MarketBeat's stock screener tool [2] - Penny stocks are defined as shares of very small or microcap companies trading at low per-share prices, traditionally under $1 but commonly under $5 in the U.S. [2] - These stocks often trade on over-the-counter markets, characterized by low liquidity, wide bid-ask spreads, high volatility, and a greater risk of price manipulation and loss [2] Group 2: Company Profiles - Beyond Meat, Inc. develops, manufactures, markets, and sells plant-based meat products across various platforms including beef, pork, and poultry, with distribution through grocery and foodservice channels [3] - Strive (Asset Entities Inc.) provides social media marketing and content delivery services, focusing on platforms like Discord and TikTok, and offers investment education and marketing services [4] - Pulmonx Corporation specializes in minimally invasive devices for chronic obstructive pulmonary diseases, offering products like the Zephyr Endobronchial Valve and Chartis Pulmonary Assessment System [5] - Datavault AI Inc. operates data management and supercomputer platforms, providing data technology and software solutions, previously known as WiSA Technologies, Inc. [6]

Group 1: Market Movements - Several healthcare and biotech stocks experienced significant gains in after-hours trading, influenced by earnings updates, executive appointments, and capital market activities [1] Group 2: Company-Specific Updates - Pulmonx Corp. (LUNG) saw a surge of 33.33% to $2.08, announcing preliminary third-quarter 2025 revenue of approximately $21.5 million and a leadership change with Glen French reappointed as President and CEO [2] - Q32 Bio Inc. (QTTB) increased by 12.5% to $3.15, although no specific news was reported to explain this rise [3] - Universal Health Services Inc. (UHS) climbed 7.41% to $229.90 after reporting third-quarter results and revising its full-year 2025 operating forecast, alongside a $1.5 billion increase in its stock repurchase program [3] - X4 Pharmaceuticals Inc. (XFOR) gained 5.35% to close at $3.94 after completing a public offering of 52.8 million shares, raising approximately $155.3 million before expenses [4] - Greenwich LifeSciences Inc. (GLSI) advanced 5.41% to $10.32 with no new developments reported [5] - Cardiff Oncology, Inc. (CRDF) moved up 5.26% to $2.41, also without any accompanying news [5]

Agreement Terms - The initial term of the agreement is from October 28, 2025, until December 1, 2025, unless terminated earlier [12]. - Either party may terminate the agreement for cause with a 15-day written notice [13]. - The agreement will be governed by the laws of the United States and the State of California [21]. - The agreement between Pulmonx Corporation and the consultant constitutes the entire agreement regarding the subject matter and supersedes all prior agreements [26]. - The agreement may only be amended by mutual written consent of authorized representatives from both parties [26]. - The agreement can be executed in multiple counterparts, which together constitute one instrument [26]. - Counterparts may be delivered via electronic means and will be considered valid and effective [26]. - The agreement was executed by Dana G. Mead, Jr., Chairman of Pulmonx Corporation [28]. - The effective date of the agreement is not specified in the provided content [28]. Consultant Responsibilities - Consultant will provide services related to ongoing financial and strategic matters for Pulmonx Corporation, with a maximum of 20 hours of work per month [3]. - Consultant is required to maintain confidentiality regarding Client's confidential information, including financial statements and business plans [9]. - Consultant agrees not to solicit any employees or contractors of the Client during the term of the agreement [16]. - Consultant must use reasonable security measures to protect any personal information in its possession [12]. - Consultant is prohibited from engaging with Olympus Corporation or its successors in the COPD business without prior written consent from the Client [17]. Compensation and Fees - Consultant will receive a fee of $30,000, payable within five days of December 1, 2025 [4]. - Consultant's equity under the 2020 Equity Incentive Plan will continue to vest during the term of the agreement [4]. - Client is responsible for all JAMS arbitration fees exceeding the administrative fees applicable in court [25]. Arbitration and Legal Provisions - The arbitrator has the authority to compel adequate discovery and award relief as permitted by law [25]. - The agreement allows for injunctive relief in court to prevent irreparable harm pending arbitration [25].